Prevalence and risk factors for Human T-Lymphotropic Virus Type 1 (HTLV-1) among maintenance hemodialysis patients by Rilma F. S. Santos et al.
RESEARCH ARTICLE Open Access
Prevalence and risk factors for Human
T-Lymphotropic Virus Type 1 (HTLV-1)
among maintenance hemodialysis patients
Rilma F. S. Santos1,2*, Gildásio C. Conceição3, Márcia S. Martins4, Angiolina Kraychete4, Maria A. C. Penalva5,
Edgar M. Carvalho6,7, Antonio Alberto Lopes4,7 and Paulo Novis Rocha2,7
Abstract
Background: Infection with the human T-cell lymphotropic virus type 1 (HTLV-1), although asymptomatic in most
cases, can lead to potentially grave consequences, such as adult T-cell leukemia-lymphoma and HTLV-1-associated
myelopathy / tropical spastic paraparesis. Its prevalence varies widely across different populations and geographic
regions. A population-based study in the city of Salvador, located in the Northeast region of Brazil, showed an overall
prevalence of HTLV-1 seropositivity of 1.7%. Blood borne virus infections are recognized as important hazards for
patients and staff in maintenance hemodialysis (MHD) units but most studies focus on hepatitis B, hepatitis C and
human immunodeficiency viruses. There are scarce data about HTLV-1 infection in the MHD population. We aimed to
determine the prevalence and risk factors for HTLV-1 infection among MHD patients in the city of Salvador-Bahia, Brazil.
Methods: We conducted a multi-center, cross-sectional study nested in a prospective cohort of MHD patients enrolled
from four outpatient clinics. HTLV-1 screening was performed with ELISA and positive cases were confirmed by
Western Blot. Factors associated with HTLV-1 seropositivity were identified by multivariable logistic regression.
Results: 605 patients were included in the study. The overall prevalence of HTLV-1 infection was 2.48% (15/605), which
was similar to that of hepatitis B [1.98% (12/605)] and C [3.14% (19/605)] viruses in our sample. HTLV-1 seropositivity
was positively associated with age [prevalence odds ratio (POR) 1.04; 95% confidence interval (CI) 1.01–1.08], unmarried
status (POR 3.65; 95% CI 1.13–11.65), and history of blood transfusion (POR 3.35; 95% CI 1.01–11.13).
Conclusions: The overall prevalence of HTLV-1 infection in a sample of MHD patients was similar to that of other viral
infections, such as hepatitis B and C. Our data revealed that MHD patients who are older, unmarried or who have
received blood transfusions are at higher risk for HTLV-1 infection.
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Background
The human T-cell lymphotropic virus type 1 (HTLV-1),
the first human retrovirus identified [1], is the etiologic
agent of adult T-cell leukemia-lymphoma (ATLL) and
HTLV-1-associated myelopathy / tropical spastic para-
paresis (HAM/TSP) [2–5]. HAM/TSP is the most severe
form of neurologic manifestation of HTLV-1 infection,
but a large percentage of infected subjects present with
milder forms of neurologic involvement, such as erectile
dysfunction or neurogenic bladder [6, 7]. Patients with
HTLV-1-related neurogenic bladder may present with
urinary symptoms that mimic urinary tract infections [8]
and ultimately evolve to obstructive kidney failure [9].
More recently, HTLV-1 infection has been linked to
other manifestations, such as uveitis, Sicca syndrome,
chronic periodontitis, infective dermatitis, polymyositis
and polyneuropathy [10–12], although most seropositive
patients remain asymptomatic for prolonged periods.
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HTLV-1 infection has become a worldwide epidemic,
but studies focusing on population prevalence are scarce
and stem mainly from endemic areas [13]. The distribu-
tion of the virus is not homogeneous and its prevalence
varies according to the geographic area and characteris-
tics of the population, with a spatial variation within
each region [13–15]. Data obtained mainly from non-
population-based studies indicate that the areas with the
highest prevalence of HTLV-1 infection are Southern
Japan, Caribbean islands, west and central regions of
Africa, Malanesia islands, some regions of the Middle
East and some regions of South America [16–19].
In Brazil, most of the prevalence data have been ob-
tained from serological screening of asymptomatic blood
donors. These data show a great variation in prevalence
within the country, being highest in the northeast region
[20–23]. In northeast Brazil, the highest prevalence of
HTLV-1 infection is observed in the city of Salvador,
capital of the state of Bahia. In a population-based study,
the overall prevalence of HTLV-1 seropositivity in Salva-
dor was 1.7% [95% CI 1.1–2.5%] [24].
Blood borne virus infections are recognized as import-
ant hazards for patients and staff in maintenance
hemodialysis (MHD) units but most studies focus on
hepatitis B (HBV), hepatitis C (HCV) and human im-
munodeficiency virus (HIV). Few studies were specifically
designed to estimate the prevalence of HTLV-1 infection
in MHD patients [25–30]. These studies, conducted in the
last century, revealed that, similarly to what is observed in
the general population, the prevalence of HTLV-1 infec-
tion among MHD patients varies according to the geo-
graphic area. In a study of patients undergoing MHD in
several regions of Japan, the average prevalence of HTLV-
1 infection was 2.7% but there was a wide variation across
regions, reaching up to 21.2% in Okinawa, a highly en-
demic area of HLTV-1 among asymptomatic blood donors
[26]. A more recent study, conducted in the Mazandaran
province in north Iran, a non-endemic region of HLTV-1,
found a prevalence of HTLV-1 of 0.6% [31]. We found no
published data about the prevalence of HTLV-1 in MHD
patients treated in Brazil.
Given the high prevalence of HTLV-1 infection in the
general population in Salvador-Bahia and the scarcity of
data about this infection in the MHD population, we
conducted a cross-sectional study nested in a prospect-
ive, multicenter cohort of MHD patients, to identify the
prevalence and factors associated with HTLV-1 seroposi-
tivity in this population.
Methods
Subjects and sites
We screened MHD patients enrolled in the Prospective
Study of the Prognosis of Chronic Hemodialysis Patients
(PROHEMO) cohort. The current phase of the PROHEMO
study cohort began in 2010; it includes MHD patients from
four (out of a total of twelve) outpatient dialysis units in the
city of Salvador, the capital of Bahia, located in the northeast
region of Brazil [32, 33]. We do not have an epidemiologic
profile of the remaining eight clinics, but we believe the four
clinics studied to be representative of all clinics in Salvador.
We included all adult (18 or older) members of the PRO-
HEMO cohort who were alive and undergoing MHD at the
time of the collection of blood samples for HTLV-1 serology
screening (between August and October 2011). At this time,
the cohort contained 695 patients; we excluded 90 patients
due to lack of essential clinical data. Therefore, our analyses
were conducted on 605 patients, corresponding to 87%
(605/695) of the entire cohort.
Design
Cross-sectional study nested in a prospective cohort study
of MHD patients. Information on socio-demographic,
laboratorial and clinical variables ware obtained directly
from the PROHEMO database, which contains data
prospectively collected from patients and medical records.
Information on HTLV-1 status was obtained by screening
stored blood samples. Between August and October 2011,
at the time of blood collection for monthly dialysis labs,
additional 10 ml samples of blood were drawn and stored
at −20 °C for future analyses. These samples were screened
for antibodies against HTLV 1/2, using an enzyme im-
munoassay (EIA) - Gold ELISA HTLV-1/2 (REM Indústria
e Comércio LTDA) and the positive cases were confirmed
by a Western Blot (WB) immunoassay (HTLV Blot 2.4, MP
Biomedicals Asia Pacific Pte Ltd. Singapore).
The economic class of the patients (A, B, C, D and E)
was determined using the classification system of the
Brazilian Institute of Market Research (Abipeme) that
considers consumer goods, such as refrigerators, televi-
sions and telephones. Patients in classes D and E were
categorized as poor or very poor [34].
A variable “history of blood transfusion” was available in
the dataset. Participants of the cohort were asked the
following question “Did you receive blood transfusion over
the past three months?” There were no data on transfusions
past this period or on the number of units transfused.
Ethical issues
All participants signed an informed consent form agree-
ing with the use of their clinical information and collec-
tion and testing of blood samples for HTVL serology for
research purposes. The medical director of each partici-
pating dialysis unit signed a consent letter approving the
study protocol. The Institutional Review Board of the
Medical School of Bahia of the Federal University of
Bahia approved the study protocol.
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Sample size calculation
In December 2011, the population of MHD patients of the
city of Salvador was estimated to be around 2000 patients
(unpublished data from the State’s Health Secretariat). Using
the software Openepi (www.openepi.com), we estimated
that 548 patients would be needed to detect a prevalence of
HTLV-1 seropositivity in MHD patients in Salvador of 2%,
with 95% confidence limits extending 1% on either side.
Statistical analyses
Continuous data were summarized using mean ± standard
deviation (SD) or median and interquartile range (IQR);
categorical variables were summarized using relative
frequencies. Comparisons of continuous variables between
seropositive and seronegative groups were performed using
the Student’s t-test for independent samples; categorical
variables were compared using the chi square (with con-
tinuity correction) or Fischer’s exact test. Variables that
showed an association with HTLV-1 seropositivity charac-
terized by a p value ≤ 0.25 in univariate analyses were se-
lected for a multivariable logistic regression model to
identify independent predictors of HTLV-1 seropositivity.
We used an automated multivariable logistic regression
method called forward stepwise. Briefly, in this method the
computer tests the variables one by one for entry into the
model, based on the significance level of the score statistic.
The variable with the smallest p value is entered into the
model (entry criterion: p < 0.05). After each entry, variables
that are already in the model are tested for possible
removal. The variable with the largest p value is removed
(removal criterion: p > 0.10), and the model is re-estimated.
Variables in the model are then evaluated again for re-
moval. When no more variables satisfy the removal criter-
ion, covariates that are not in the model are evaluated for
entry. Model building stops when no more variables meet
entry or removal criteria or when the current model is the
same as a previous model. A p value ≤ 0.05 in final analyses
was considered statistically significant. The analyses were
performed using SPSS for Windows version 21.0 and the
95% confidence interval of the HTLV-1 prevalence was cal-
culated using the bootstrap (50 replications) of the STATA,
version 12.0.
Results
Sixteen patients were HTLV-1 seropositive by the ELISA
technique but one was considered a false positive due to
a negative Western Blot. Therefore, 15 out of 605 MHD
patients studied had confirmed HTLV-1 infection, for an
overall prevalence of 2.48% (95% CI 1.22–3.74%). There
were no cases of HTLV-2 seropositivity in our sample.
In two out of these fifteen cases (13.3%), the ESRD was
attributed to urological complications of HTLV-1 infec-
tion, specifically neurogenic bladder leading to obstructive
kidney failure. The first case was a 70 year-old female,
wheelchair-bound due to HAM/TSP secondary to HTLV-
1. She had a well-documented case of neurogenic bladder
and was followed by a team of Neurologists and Urolo-
gists at an ambulatory clinic specialized in HTLV-1 at the
University Hospital of the Federal University of Bahia. She
did not have diabetes or hypertension and other causes of
ESRD were excluded on clinical grounds. The second case
was a 47 year-old man who initially presented to the
emergency department of a public general hospital with
uremia. He was found to have a distended bladder and bi-
lateral hydronephrosis on ultrasound, with a normal-sized
prostate gland. A Foley catheter was placed, but renal fail-
ure did not improve and he remained dialysis-dependent.
He had no prior history of hypertension or diabetes.
Table 1 shows the socio-demographic, clinical and
laboratorial characteristics of our sample, stratified by
HTLV-1 serology. In this univariate analysis, unmarried
status and a history of blood transfusion were the only
variables significantly associated with a positive HTLV-1
serology. The mean age tended to be greater and time on
dialysis tended to be lower in the seropositive group.
Overall, there were 12/604 patients (1.99%) with HBV and
19/605 (3.14%) with HCV; the frequency of positive HBV
or HCV serology tended to be higher in the HTLV-1
group. Seropositive patients also had higher serum cre-
atinine, higher parathyroid hormone (PTH) and lower
leucocyte count whereas hemoglobin levels did not differ
among groups (data not shown).
Figure 1 shows the prevalence and prevalence ratio of
HTLV-1 seropositivity in subgroups of MHD patients. The
highest prevalence ratios were encountered in those who
received blood transfusions, unmarried and with HBV or
HCV. The prevalence of HTLV-1 infection also increased
with age, going from 1.6 to 2.2% and 2.9% among those
18–30, 31–50 and > 50 years old, respectively.
Table 2 shows the multivariable logistic regression to
identify variables independently associated with HTLV-1
seropositivity. In this analysis, the variables that showed
statistically significant associations with HTLV-1 sero-
positivity were older age, unmarried status and a history
of blood transfusion.
Discussion
Our initial hypothesis was that the prevalence of HTLV-1
in the MHD population would be greater than that ob-
served in the general population. This hypothesis was based
on older literature data from other countries [27–29, 35]
and on the following postulates: a) ESRD could be a risk
factor for HTLV-1, mediated by anemia and greater fre-
quency of blood transfusion or due to the risk of acquiring
the virus during the hemodialysis procedure, as it is known
to happen with HBV and HCV [36, 37]; b) HTLV-1 and
end stage renal disease (ESRD) could share risk factors,
such as poverty and health illiteracy [38, 39]; c) HTLV-1
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could be a risk factor for ESRD as the urological manifesta-
tions of the virus, such as neurogenic bladder, can lead to
post-renal kidney failure [9]. Nevertheless, the overall
prevalence of HTLV-1 seropositivity in our sample of 605
MHD patients was 2.48% (95% CI 1.22–3.74%), which is
only marginally higher than that observed by Dourado et al.
in a population-based study in the city of Salvador (1.7;
95% CI 1.1–2.5%) [24].
In their study, Dourado et al. studied individuals from 1 to
89 years. The prevalence of HTLV-1 infection increased with
age, going from 0.3 to 1.1 to 1.1 and 8.4% among those 0–15,
16–30, 31–50 and > 50 years old, respectively. In the present
study of MHD patients, the prevalence of HTLV-1 infection
also increased with age, going from 1.6% in those 18–30 to
2.9% among those > 50 years old; for every increase in one
year of age, we found a 4% increase in the odds of having a
positive HTLV-1 serology. A potential explanation for this as-
sociation is that increasing age provides a greater length of
exposure to events that might result in acquiring the virus,
such as sexual activity, intravenous drug use or blood transfu-
sion. Since there is no cure for HTLV-1, once acquired, the
infection is carried forward over time (cohort effect).
Table 1 Demographic, clinical and laboratorial variables of 605 maintenance hemodialysis patients from four outpatient dialysis
units in Salvador, Bahia, Brazil, stratified by HTLV-1 serology








Age, years 52.5 (46.9–71.0) 47.8 (37.7–59.0) 1.03 (1.00–1.07) 0.080
Female (vs. male) 8/15 (53.3) 224/590 (38.0) 1.87 (0.67–5.22) 0.234
Non-white (vs. white) 13/15 (86.7) 513/590 (86.9) 1.03 (0.23–4.63) 0.974
Poor or very poor (vs. classes A thru C) 10/15 (66.7) 265/580 (45.7) 2.38 (0.80–7.04) 0.118
Less than high school (vs. high school or greater) 12/15 (80.0) 359/589 (61.0) 2.56 (0.72–9.18) 0.148
Unmarried (vs. married) 11/15 (73.3) 261/588 (44.4) 3.45 (1.09–10.95) 0.036
Clinical
Dialysis by catheter (vs. AV fistula) 4/15 (26.7) 76/588 (12.9) 1.12 (0.31–4.02) 0.867
Time on MHD, months 20.4 (4.5–58.4) 47.8 (19.6–97.4) 0.99 (0.97–1.00) 0.064
EPO, IU (x103)/week 12 (6–12) 10 (6–12) 1.00 (1.00–1.00) 0.870
Diabetes mellitus (vs. no) 5/15 (33.3) 100/590 (16.9) 2.45 (0.82–7.32) 0.109
Systemic hypertension (vs. no) 13/15 (86.7) 533/590 (90.3) 0.70 (0.15–3.16) 0.638
Blood transfusion (vs. no) 4/15 (26.7) 55/582 (9.2) 3.48 (1.07–11.31) 0.038
Hepatitis B (vs. no) 1/15 (6.7) 11/589 (1.9) 3.75 (0.45–31.10) 0.220
Hepatitis C (vs. no) 1/15 (6.7) 18/590 (3.1) 2.27 (0.28–18.21) 0.440
Hepatitis B or C (vs. no) 2/15 (13.3) 28/589 (4.8) 3.08 (0.66–14.33) 0.151
Continuous data (Age, Time on MHD and EPO dose) are expressed as median (P25–P75%); categorical data are expressed as n/total (%); POR Prevalence Odds
Ratio, EPO Erythropoietin, MHD maintenance hemodialysis. For continuous data, POR reflects the odds of a positive HTLV serology with each increase in one unit
of the continuous variable (one year for Age, one month for Time on MHD, and 103 IU/week for EPO); for categorical data, POR reflects the odds of a positive
HTLV serology in the variable of interest compared to its complement. History of blood transfusion was limited to available data that reported transfusion only for
the previous three months. P values in bold highlight the variables that were selected for the multivariable logistic regression model. Although a positive serology
for Hepatitis B was associated with a p ≤ 0.25, it was not included in the multivariable model because we preferred to use the variable Hepatitis B or C
Fig. 1 Prevalence and prevalence ratio of HTLV-1 seropositivity in subgroups of maintenance hemodialysis patients from four satellite clinics in
Salvador, Bahia, Brazil
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The association between HTLV-1 infection and blood
transfusion is well established and has been confirmed in
several studies using blood donors in different countries
[39–41], including Brazil [38]. Blood transfusions among
MHD patients were much more common before the
advent of recombinant human erythropoietin (rhEPO)
[42, 43]; indeed, this might help explain the high
prevalence of HTLV-1 in the MHD population of some
Japanese studies published before the advent of rhEPO
[25, 26]. Currently, the routine use of rhEPO markedly re-
duced the need for blood transfusion, particularly among
those patients who are already established on MHD pro-
grams for more than three months [44].
In Brazil, however, there is still a considerable need for
blood transfusions among patients who are recent on
MHD, since many of them start dialysis emergently, with-
out the benefit of pre-dialysis medical care. This was illus-
trated in a study conducted at the largest public hospital
in Salvador [45], which is a referral service for the entire
state of Bahia. The authors studied all patients who initi-
ated MHD at that institution after being admitted through
the emergency department and found that 57% of them
first learned about their kidney disease at the time of
diagnosis of ESRD. Moreover, 71% of them had not been
evaluated by a nephrologist before arriving at the emer-
gency department. Their mean hemoglobin at admission
was 7.7 mg/dL; no patient had received rhEPO previously
and 50% of them required blood transfusion during the
hospitalization [45]. In the present study, we found that a
history of blood transfusion tripled the odds of having a
positive HTLV-1 serology. Spread of HTLV-1 during the
hemodialysis procedure seems less likely, based on the
biology of the virus. Some studies indicate that transmis-
sion of HTLV-1 requires the contact between living cells
and not simply cell-free body fluids [46, 47].
In their population-based study, Dourado et. al showed
that the prevalence of HTLV-1 was greater among fe-
males, those with lower income, worse living conditions
and less education [24]. In the present study of the
MHD population, we also found a numerically higher
prevalence of HTLV-1 infection among females, those
who were poor or very poor and those who had less
than high school education, although these associations
did not reach statistical significance. Unmarried status,
however, more than tripled the odds of having a positive
HTLV-1 serology. We posit that unmarried status might
have functioned as a proxy for sexual promiscuity and/
or unprotected sex, which are known risk factors for
HTLV-1 infection [38, 39].
In Brazil, the main etiologies of ESRD are hypertension
(35%), diabetes mellitus (30%), chronic glomeruloneph-
ritis (12%) and polycystic kidney disease (4%) [48].
Herein, urological complications of HTLV-1 infection
were felt to be the cause of ESRD in only 0.3% of pa-
tients (2/605). We are not aware of other studies that
evaluated the contribution of HTLV-1 to ESRD.
Our study has several limitations. An inherent limitation
of cross sectional studies is that associations do not imply
causality. We utilized the database of an ongoing multi-
center cohort study of MHD in our area and all of our
analyses were limited to the variables that were present in
their database. We did not have information on sexual
practices, living conditions, intravenous drug use or
neurologic symptoms. Moreover, our data on blood trans-
fusion was categorical (yes/no) and restricted to the previ-
ous three months; we had no information on lifetime
exposure to blood products. Finally, our study provides no
information about HIV co-infection as none of the four
MHD units studied admit HIV positive patients.
Conclusion
The prevalence of HTLV-1 infection in MHD patients
from four hemodialysis units in northeast Brazil was not
higher than that encountered in a population-based
study of the same geographic area. HTLV-1 seropositiv-
ity in MHD patients was similar to that of other viral in-
fections, such as HBV and HCV. Older age, unmarried
status and blood transfusions were independently associ-
ated with HTLV-1 infection.
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